Skip to main content

GLP1 Receptor Agonists Do Not Up Risk for Complications After Emergency Surgery

Medically reviewed by Carmen Pope, BPharm. Last updated on April 25, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, April 25, 2024 -- The risk for postoperative respiratory complications is similar among patients undergoing emergency surgery regardless of preoperative glucagon-like peptide 1 receptor agonist (GLP-1 RA) use, according to a research letter published online April 22 in the Journal of the American Medical Association.

Anjali A. Dixit, M.D., M.P.H., from Stanford University in California, and colleagues used a claims database to evaluate the risk for postoperative respiratory complications among patients with type 2 diabetes and a prescription fill for GLP-1 RAs who underwent one of 13 emergency surgeries. The analysis included data identified from the Merative MarketScan Commercial Database (2015 through 2021).

The researchers found that among 23,679 patients with diabetes and emergency surgery, 14.8 percent had a GLP-1 RA fill. A GLP-1 RA fill was associated with a greater likelihood of being male, using more antidiabetic agents, and having diagnoses of obesity. The overall incidence of postoperative respiratory complications was similar for those with a GLP-1 RA fill and those without (3.5 versus 4.0 percent; odds ratio, 0.85; 95 percent confidence interval, 0.70 to 1.04). Findings were similar in an adjusted analysis (odds ratio, 1.03; 95 percent confidence interval, 0.82 to 1.29).

"Results of this study suggest that liberalizing the withholding guidelines for GLP-1 RAs preoperatively should be considered," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease

FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...

ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma

WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...

Diabetes Tied to Higher Prevalence of Overactive Bladder

TUESDAY, June 4, 2024 -- Markers of diabetes are positively associated with overactive bladder (OAB), according to a study published online April 28 in Frontiers in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.